Other languages 3SBio Inc. BOERSE MUENCHEN

Equities

83B

KYG8875G1029

Real-time BOERSE MUENCHEN Other stock markets 06:14:07 2024-07-17 am EDT			5-day change	1st Jan Change
0.785 ^EUR	0.00%		+3.97%	-7.65%

Jun. 25	3Sbio Inc. Announces Board Changes	CI
May. 29	3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

3Sbio Inc. Declares Final Dividend for the Year Ended 31 December 2023, Payable on 5 August 2024	Jun. 25
3Sbio Inc. Announces Board Changes	Jun. 25
3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	May. 29
3Sbio Inc. Announces Board and Committee Changes	Apr. 22
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication	Apr. 12
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.	Mar. 27
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates	Mar. 20
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024	Mar. 20
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product	Jan. 08
Mandi Foam of 3SBio Inc. Approves for Market Launch	Jan. 08
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	Nov. 02
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates	23-08-25
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24
3SBio Hires Former JPMorgan Exec as CFO	23-07-31
3SBio Rolls Out Pruritus Medication in China	23-07-06
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market	23-07-05
3SBio Enrolls First Patient in Phase 3 Trial of Thrombocytopenia Treatment	23-05-22
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 11 July 2023	23-05-22
3SBio Inc. Announces First Patient Enrolled in the Trial of Phase III Clinical Study of Recombinant Human Thrombopoietin Injection	23-05-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 3SBio Inc. BOERSE MUENCHEN

Equities

83B

KYG8875G1029

Other languages

Filters